FogPharma’s $178M Raise, MassBio’s New Training Center, and More Boston Tech News

November 28, 2022
Assembly Row in Somerville
Assembly Row in Somerville. | Photo: Shutterstock

With Thanksgiving in the rearview mirror, it’s time to look back at all of the local tech news you may have missed in between trips to the grocery store, road trips to visit your in-laws and turkey-induced naps on the couch. Keep reading for the latest tech scene developments, including a way to break into Boston’s booming biotech scene. This is the Built In Boston Weekly Refresh. 

SmartBear expanded its office space. The company, which is known for software development tools like SwaggerHub and ReadyAPI, added another 16,000 square feet to its office at the Assembly Row shopping center in Somerville. The company, which has 260 local employees, signed a seven-year lease on the 52,414-square-foot space. [Built In Boston]

Boston Tech Quote of the Week

“As the leading global hub for life sciences, we have an obligation and an opportunity to connect Boston residents to good-paying jobs in the industry. We must set ambitious goals to train and employ residents, meet the workforce needs of the sector and empower our communities.” — Boston Mayor Michelle Wu

MassBio announced a new workforce training center. MassBio, a nonprofit working to advance life sciences innovation in Massachusetts, is partnering with Beacon Capital Partners and the city of Boston to develop the MassBio Training Center. The center will offer three tracks of training for people looking to break into the region’s booming biopharmaceutical industry. The free training sessions will offer a stipend and pay for wraparound services. The 4,000-square-foot center is expected to open next September at the former Boston Globe headquarters in Dorchester. [Boston Business Journal]

FogPharma raised $178M. The Cambridge-based biopharmaceutical company is leading the development of Helicon polypeptides through a new approach that may be able to reach cancer targets previously considered to be “undruggable,” according to the company. The company’s lead therapeutic is expected to enter clinical development in mid-2023. [Business Wire]

Boston startup guides

Best Companies to Work for in Boston
Coolest Tech Offices in Boston
Best Perks at Boston Tech Companies
Women in Boston Tech